Publication | Closed Access

Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models

Tumor BiologyMedicinePharmacologyEgfr-expressing Tumor ModelsAntitumor EfficacyExtracellular MicrovesiclesTumor TargetingAnti-cancer AgentOncologyCell BiologyCancer ResearchCancer GrowthDoxorubicin Liposomes